Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoposide-induced pulmonary toxicity.

A Gurjal1, T An, M Valdivieso

  • 1The Department of Internal Medicine, Wayne State University and the Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.

Lung Cancer (Amsterdam, Netherlands)
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterizing the CO<sub>2</sub>-response curve in photosynthesis and photorespiration: an innovative model for C<sub>3</sub> plant species.

Photosynthetica·2026
Same author

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

ESMO open·2025
Same author

Charting achievements: a two-year retrospective of the society for environmental geochemistry and health (SEGH) and the evolving strategies.

Environmental geochemistry and health·2024
Same author

[Clinical characteristics of patients referred to cardio-oncology clinic].

Zhonghua yi xue za zhi·2023
Same author

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

GaLactic and Extragalactic All-sky Murchison Widefield Array survey eXtended (GLEAM-X) I: Survey Description and Initial Data Release.

Publications of the Astronomical Society of Australia : PASA·2022
Same journal

Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Corrigendum to "European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" Published in [Lung Cancer https://doi.org/10.1016/j.lungcan.2026.109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Genome-wide copy number analysis identifies AKT as a novel therapeutic target in pleural mesothelioma.

Lung cancer (Amsterdam, Netherlands)·2026
See all related articles

Etoposide treatment can cause lung disease in cancer patients, leading to respiratory failure. Steroids may help, but symptoms can return if etoposide is readministered.

Area of Science:

  • Oncology
  • Pulmonology
  • Toxicology

Background:

  • Etoposide is a chemotherapy agent commonly used for lung cancer.
  • Drug-induced lung disease is a potential adverse effect of various chemotherapeutic agents.

Observation:

  • Two lung cancer patients developed interstitial infiltrates and respiratory failure after etoposide treatment.
  • One patient showed rapid improvement with steroid therapy but experienced symptom recurrence upon etoposide re-challenge.

Findings:

  • Histopathologic examination confirmed drug-induced pulmonary toxicity in both patients.
  • The clinical presentation and response to therapy suggest a specific etoposide-induced lung injury.

Implications:

  • Etoposide-induced lung disease should be considered in patients presenting with subacute dyspnea and interstitial infiltrates during etoposide therapy.

Related Experiment Videos

  • Awareness of this toxicity can guide timely diagnosis and management, potentially improving patient outcomes.